Researchers find interferon has both detrimental and beneficial effects on SIV infected rhesus macaques

July 10, 2014 by Bob Yirka, Medical Xpress report
Diagrammatical representation of the molecular structure of HIV-1 protease complexed with the inhibitor indinavir. Credit: Public Domain

(Medical Xpress)—A large team of researchers with affiliations to several facilities in the U.S. and Israel has found that administering Type 1 interferon to rhesus macaques infected with Simian Immunodeficiency Virus (SIV) can have both beneficial and detrimental effects. In their paper published in the journal Nature, the team describes how they found different impacts of interferon on the monkeys depending on when it was administered. Amalio Telenti, of the Institute of Microbiology at the University of Lausanne offers a News & Views piece on this new research in the same journal.

SIV is the simian variety of HIV, which of course is the virus that leads to AIDS in humans. Not long after HIV and AIDS became known in the early 80's, researchers began using interferon as a drug to help prevent HIV from blossoming into AIDS. Interferon is a protein created in the body and released by cells to respond to assumed pathogens such as parasites, bacteria, viruses and even tumors. Adding to the interferon already present, it was hoped would offer even more benefits. Unfortunately, as research continued, little benefit was found when giving interferon to HIV and AIDS patients, causing researchers to look for and find other drugs. In this new effort, the researchers have returned to the idea of using interferon as an HIV therapy by studying its simian counterpart. Thus far, they have found that the results of earlier research didn't take into account when the protein was administered and because of that doctors weren't able to see the beneficial impact the protein could have in inhibiting the progression of the disease.

The researchers actually found two things, the first was that administering interferon to rhesus before they were exposed to SIV helped prevent an infection—doing the opposite by giving them an antagonist of the interferon receptor, led to serious infections. The other thing they found was that timing was important when giving interferon to already infected monkeys.

The researchers found that if they gave the interferon during the early stages of SIV infection, the protein actually helped slow the infection by slowing the inflammation that occurred as part of the immune system response. But, giving them interferon after the infection was already established appeared to only make things worse. Thus, they conclude, may yet prove to be a valuable therapy for HIV patients, though studies will have to be conducted to determine if it behaves the same way in people, and if it does, if there is a way to determine when the beneficial stage has ended.

Explore further: New monkey model for AIDS offers promise for medical research

More information: Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression, Nature (2014) DOI: 10.1038/nature13554

Abstract
Inflammation in HIV infection is predictive of non-AIDS morbidity and death1, higher set point plasma virus load and virus acquisition; thus, therapeutic agents are in development to reduce its causes and consequences. However, inflammation may simultaneously confer both detrimental and beneficial effects. This dichotomy is particularly applicable to type I interferons (IFN-I) which, while contributing to innate control of infection, also provide target cells for the virus during acute infection, impair CD4 T-cell recovery, and are associated with disease progression. Here we manipulated IFN-I signalling in rhesus macaques (Macaca mulatta) during simian immunodeficiency virus (SIV) transmission and acute infection with two complementary in vivo interventions. We show that blockade of the IFN-I receptor caused reduced antiviral gene expression, increased SIV reservoir size and accelerated CD4 T-cell depletion with progression to AIDS despite decreased T-cell activation. In contrast, IFN-α2a administration initially upregulated expression of antiviral genes and prevented systemic infection. However, continued IFN-α2a treatment induced IFN-I desensitization and decreased antiviral gene expression, enabling infection with increased SIV reservoir size and accelerated CD4 T-cell loss. Thus, the timing of IFN-induced innate responses in acute SIV infection profoundly affects overall disease course and outweighs the detrimental consequences of increased immune activation. Yet, the clinical consequences of manipulation of IFN signalling are difficult to predict in vivo and therapeutic interventions in human studies should be approached with caution.

Related Stories

New monkey model for AIDS offers promise for medical research

June 19, 2014
HIV-1, the virus responsible for most cases of AIDS, is a very selective virus. It does not readily infect species other than its usual hosts – humans and chimpanzees. While this would qualify as good news for most mammals, ...

Can marijuana protect the immune system against HIV and slow disease progression?

February 18, 2014
New evidence that chronic intake of THC, the primary psychoactive ingredient in marijuana, can protect critical immune tissue in the gut from the damaging effects of HIV infection is reported in AIDS Research and Human Retroviruses.

Predicting the outcome of hepatitis C virus treatment

July 1, 2014
Millions of people throughout the world are infected with hepatitis C virus (HCV), which can lead to cirrhosis of the liver and cancer. Directly acting antiviral agents inhibit viral proteins and have been used to successfully ...

Which interferons best control viral infections?

June 26, 2014
Respiratory and intestinal infections caused by RNA viruses stimulate infected cells to produce interferons, which can act alone or in combination to block virus replication. Important differences between the presence of ...

Breakthrough in HIV/AIDS research gives hope for improved drug therapy

May 16, 2014
The first direct proof of a long-suspected cause of multiple HIV-related health complications was recently obtained by a team led by the University of Pittsburgh Center for Vaccine Research (CVR). The finding supports complementary ...

Invisibility cloak for immune cells

June 25, 2014
The human immune system is very complex. A large number of different cells with various functions ensure that invading microorganisms such as viruses or bacteria can quickly be rendered innocuous and the entire organism stays ...

Recommended for you

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

Researchers find clues to AIDS resistance in sooty mangabey genome

January 3, 2018
Peaceful co-existence, rather than war: that's how sooty mangabeys, a monkey species found in West Africa, handle infection by SIV, a relative of HIV, and avoid developing AIDS-like disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.